Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women

被引：10
|
作者：
Vogelvang, TE
Mijatovic, V
Kenemans, P
Schalkwijk, CG
van der Mooren, MJ
机构：
[1] Vrije Univ Amsterdam, Med Ctr, Dept Obstet & Gynecol, ICaR, NL-1007 MB Amsterdam, Netherlands
[2] Vrije Univ Amsterdam, Med Ctr, Dept Clin Chem, ICaR, NL-1007 MB Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Med Ctr, Project Aging Women, NL-1007 MB Amsterdam, Netherlands
来源：
AMERICAN JOURNAL OF CARDIOLOGY | 2004年 / 94卷 / 09期
关键词：
D O I：
10.1016/j.amjcard.2004.07.099
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
We investigated the 12-week effects of 3 doses of HMR 3339, a novel selective estrogen receptor modulator, in comparison with raloxifene and placebo, on plasma concentrations of C-reactive protein in 96 healthy postmenopausal women. A dose-dependent reduction in C-reactive protein was observed, the largest reduction with HMR 3339 50 mg. (C) 2004 by Excerpta Medica, Inc.
引用
收藏
页码：1205 / 1208
页数：4
相关论文
共 50 条
  • [21] Serum oestradiol levels are inversely associated with C-reactive protein levels in premenopausal women, but not postmenopausal women
    Park, Jae-Min
    Lee, Yong-Jae
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2020, 48 (10)
  • [22] Effects of estrogen and the selective estrogen receptor modulator raloxifene on markers of inflammation in postmenopausal women
    Blum, A
    Schenke, WH
    Hathaway, L
    Mincemoyer, R
    Csako, G
    Waclawiw, MA
    Cannon, RO
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2000, 86 (08): : 892 - +
  • [23] Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women
    Koh, KK
    Schenke, WH
    Waclawiw, MA
    Csako, G
    Cannon, RO
    [J]. CIRCULATION, 2002, 105 (13) : 1531 - 1533
  • [24] Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women
    Wakatsuki, A
    Okatani, Y
    Fukaya, T
    [J]. CIRCULATION, 2002, 106 (24) : E198 - E198
  • [25] Serum levels of C-reactive protein are associated with obesity, weight gain, and hormone replacement therapy in healthy postmenopausal women
    Barinas-Mitchell, E
    Cushman, M
    Meilahn, EN
    Tracy, RP
    Kuller, LH
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2001, 153 (11) : 1094 - 1101
  • [26] Increased C-reactive protein levels during short-term hormone replacement therapy in healthy postmenopausal women
    van Baal, WM
    Kenemans, P
    van der Mooren, MJ
    Kessel, H
    Emeis, JJ
    Stehouwer, CDA
    [J]. THROMBOSIS AND HAEMOSTASIS, 1999, 81 (06) : 925 - 928
  • [27] LASOFOXIFENE, A SELECTIVE ESTROGEN RECEPTOR MODULATOR, AS A TREATMENT FOR SEXUAL DYSFUNCTION IN POSTMENOPAUSAL WOMEN
    Kingsberg, S.
    Simon, J.
    Symons, J.
    Portman, D.
    [J]. JOURNAL OF SEXUAL MEDICINE, 2016, 13 (05): : S4 - S5
  • [28] Weight loss reduces C-reactive protein levels in obese postmenopausal women.
    Tchernof, A
    Nolan, A
    Sites, CK
    Ades, PA
    Poehlman, ET
    [J]. FASEB JOURNAL, 2002, 16 (05): : A1015 - A1015
  • [29] Focus on raloxifene: A selective estrogen receptor modulator for prevention of osteoporosis in postmenopausal women
    Ashworth, LE
    [J]. FORMULARY, 1998, 33 (04) : 305 - +
  • [30] Effect of bisphosphonate therapy on C-reactive protein in postmenopausal women with primary hyperparathyroidism
    Nicasio, John
    Joseph, Linda
    Shin, John
    Deshmukh, Mrunalini
    McFarlane, Samy I.
    [J]. JOURNAL OF WOMENS HEALTH, 2006, 15 (06) : 683 - 683
12345